A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

This study is looking at how a cancer drug called capivasertib behaves in the body of people with moderate liver problems. When the liver isn't working normally, it can affect how drugs are processed — this study helps researchers understand if dose adjustments are needed for patients with liver disease. **You may be eligible if...** - You have moderate liver impairment (classified as Child-Pugh Class B) - You weigh at least 50 kg and have a BMI between 18 and 40 - You are a non-smoker (stopped at least 3 months ago) - You have stable liver disease (not rapidly worsening) **You may NOT be eligible if...** - You have severe or uncontrolled medical conditions (uncontrolled high blood pressure, active bleeding disorders, kidney transplant) - You have moderate or severe kidney problems - You have HIV, active hepatitis B, or hepatitis C - You have rapidly deteriorating liver function, liver cancer, or severe complications like major bleeding from the esophagus - You have had a liver transplant or severe liver encephalopathy (brain confusion due to liver failure) - Your blood sugar levels are poorly controlled (HbA1c of 8% or higher) Talk to your doctor to see if this trial is right for you.